sonelokimab
Sponsor Moonlake Immunotherapeutics · listed as MLTX
READOUT
Phase 3
Confidence: medium
Source: clinicaltrials
Next catalyst
Event typeREADOUT
Expected date2026-09-28
As disclosedSep 28, 2026
Date precisionday
Confidencemedium
Trial & sponsor
Trial (NCT)NCT06768671
PhasePHASE3
StatusACTIVE_NOT_RECRUITING
Lead sponsorMoonLake Immunotherapeutics AG
Listed asMLTX
Condition(s)Hidradenitis Suppurativa
All tracked catalysts for sonelokimab
| Date | Event | Confidence | Trial |
|---|---|---|---|
| 2026-09-28 | READOUT | medium | NCT06768671 |
| 2027-01-15 | READOUT | medium | NCT06641089 |
| 2027-02-04 | READOUT | medium | NCT06641076 |
!
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.
Get the full dataset — $499 → More MLTX catalysts